Logo 1.png
Aeterna Zentaris Announces Continued Expansion of Intellectual Property Portfolio for Macimorelin with Additional Patent Applications
July 31, 2020 07:35 ET | Aeterna Zentaris Inc
CHARLESTON, S.C., July 31, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...
Logo 1.png
Aeterna Zentaris Receives Nasdaq Notification Regarding Minimum Bid Price Compliance; No Immediate Impact on Listing
July 29, 2020 07:05 ET | Aeterna Zentaris Inc
CHARLESTON, S.C., July 29, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna Zentaris” or the “Company”), a specialty biopharmaceutical company commercializing and...
Logo 1.png
AETERNA ZENTARIS ANNOUNCES CLOSING OF $12 MILLION PUBLIC OFFERING
July 07, 2020 16:05 ET | Aeterna Zentaris Inc
CHARLESTON, S.C., July 07, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing...
Logo 1.png
AETERNA ZENTARIS ANNOUNCES DISTRIBUTION AGREEMENT WITH MEGAPHARM LTD. TO COMMERCIALIZE MACIMORELIN IN ISRAEL AND THE PALESTINE AUTHORITY
June 25, 2020 08:00 ET | Aeterna Zentaris Inc
CHARLESTON, S.C, June 25, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing...